Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Other Non-Current Assets: 2013-2024

Historic Other Non-Current Assets for Ocular Therapeutix (OCUL) over the last 12 years, with Dec 2024 value amounting to $1.6 million.

  • Ocular Therapeutix's Other Non-Current Assets changed negligibly% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $1.6 million for FY2024, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Ocular Therapeutix reported Other Non-Current Assets of $1.6 million as of FY2024, which was down 0.00% from $1.6 million recorded in FY2023.
  • Ocular Therapeutix's Other Non-Current Assets' 5-year high stood at $1.8 million during FY2020, with a 5-year trough of $1.6 million in FY2023.
  • Moreover, its 3-year median value for Other Non-Current Assets was $1.6 million (2024), whereas its average is $1.7 million.
  • Data for Ocular Therapeutix's Other Non-Current Assets shows a maximum YoY decreased of 8.50% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Ocular Therapeutix's Other Non-Current Assets stood at $1.8 million in 2020, then remained steady at $1.8 million in 2021, then remained steady at $1.8 million in 2022, then dropped by 8.50% to $1.6 million in 2023, then remained steady at $1.6 million in 2024.